Previous Close | 160.26 |
Open | 160.74 |
Bid | 157.70 x 900 |
Ask | 159.76 x 800 |
Day's Range | 158.50 - 161.61 |
52 Week Range | 117.64 - 169.98 |
Volume | |
Avg. Volume | 509,975 |
Market Cap | 9.949B |
Beta (5Y Monthly) | 0.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.37 |
Earnings Date | Aug 03, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 201.89 |
Subscribe to Yahoo Finance Plus to view Fair Value for JAZZ
The mean of analysts' price targets for Jazz (JAZZ) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
JAZZ vs. CORT: Which Stock Is the Better Value Option?
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) to $204 with a reiterated Buy rating on slightly increased forward EPS estimates. Jazz reported a thorough 2Q22 beat, with broad product outperformance vs. consensus across neuro and oncology, plus gross margin upside and light OPEX, HC Wainwright notes. As per the analyst, this looked to be Jazz’s second-biggest operating cash flow quarter ever, pushing net leverage down to 3.2x, six months ahead of the targeted